Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome

Blood (2025) 146 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2025-3165

Published: 2025

Journal Articles

Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study

Jose Torregrosa, Thomas Brunet, Lin-Pierre Zhao, Pierre Fenaux, Arsene Mekinian, Maria Julia Montoro, David Valcarcel, Sophie Dimicoli-Salazar, Estibaliz Lazarro, Claudio Fozza, Yohann Foucher

Blood (2025) 146 (Supplement 1): 2076.

https://doi.org/10.1182/blood-2025-2076

Published: 2025

Journal Articles

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Blood (2025) 146 (Supplement 1): 454.

https://doi.org/10.1182/blood-2025-454

Published: 2025

Journal Articles

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Blood (2025) 146 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2025-5294

Published: 2025

Journal Articles

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Blood (2025) 146 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2025-4350

Published: 2025

Journal Articles

Lupus-like manifestations in MDS/CMML: Evidence for clonal origin and therapeutic implications

Blood (2025) 146 (Supplement 1): 7387.

https://doi.org/10.1182/blood-2025-7387

Published: 2025

Journal Articles

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Armelle Otiniano, Vincent Jachiet, Jerome Hadjadj, Mael Heiblig, Pierre LOZAC H, Mathieu Wemeau, Maxime Battistella, Mirabelle Ruyer Thompson, Eve Zakine, Urbain Tauveron-Jalenques, Marc Ruivard, Benoit De Renzis, Pierre Fenaux, Olivier Fain, Lin-Pierre Zhao, Arsene Mekinian

Blood (2025) 146 (Supplement 1): 5630.

https://doi.org/10.1182/blood-2025-5630

Published: 2025

Journal Articles

Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome

Blood (2025) 146 (16): 1950–1963.

https://doi.org/10.1182/blood.2024028216

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jérôme Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean-Benoît Arlet, Jérémie Dion, Maël Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thépot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoît Faucher, Estibaliz Lazaro, Véronique Morel, Antoine Néel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cédric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean-Baptiste Rieu, Olivier Fain, Sophie Georgin-Lavialle, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène Mékinian, Thibault Comont

Blood (2025) 146 (12): 1450–1461.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Gianluca Asti, Saverio D'Amico, Luciana Carota, Davide Piscia, Francesco Casadei, Nono Saha Cyrille Merleau, Patricia Alonso de Apellániz, Anne Sophie Kubasch, Silke Gloaguen, Nicole Modler, Catalina Gonzalez Martin, Cesare Rollo, Juan Parras, Mattia Delleani, Elena Zazzetti, Elisabetta Sauta, Nico Curti, Nicolas Riccardo Derus, Gianluca Carlini, Daniele Dall'Olio, Claudia Sala, Lorenzo Dall'Olio, Luca Lanino, Giulia Maggioni, Alessia Campagna, Marilena Bicchieri, Arturo Bonometti, Cesare Lancellotti, Daoud Rahal, Luca Di Tommaso, Tiziana Sanavia, Piero Fariselli, Matteo Zampini, Matteo Brindisi, Victor Savevski, Uwe Platzbecker, Maria Diez-Campelo, Lin Pierre Zhao, Pierre Fenaux, Torsten Haferlach, Vincent Planat, Raffaella Colombatti, Maria del Mar Mañú-Pereira, Anders Krogh, Silvia Uribe, Santiago Zazo, Enrico Giampieri, Gastone Castellani, Matteo Giovanni Della Porta, Federico Alvarez

Blood (2024) 144 (Supplement 1): 4989.

https://doi.org/10.1182/blood-2024-205541

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

Lin Pierre Zhao, Typhaine Dumas-Rivero, Lauren Barette, Lorea Aguinaga, Arij Cheffai, Pierre Lemaire, Stéphanie Mathis, Clémentine Chauvel, Reinaldo Dal Bello, Emmanuelle Clappier, Matthieu Duchmann, Pierre Fenaux, Marie Sebert, Lionel Ades, Raphael Itzykson

Blood (2024) 144 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2024-203353

Published: 2024

Journal Articles

Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group

Mael Heiblig, Vincent Jachiet, Jerome Hadjadj, Lin Pierre Zhao, Thibault Comont, Hervé Lobbes, Valentin Lacombe, Anne Blandine Boutin, Joris Galland, Yesim Dargaud, Benjamin Terrier, Sophie Georgin-Lavialle, Pierre Fenaux, Arsene Mekinian

Blood (2024) 144 (Supplement 1): 2674.

https://doi.org/10.1182/blood-2024-210879

Published: 2024

Journal Articles

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2023-186222

Published: 2023

Journal Articles

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Blood (2023) 142 (Supplement 1): 122.

https://doi.org/10.1182/blood-2023-188292

Published: 2023

Journal Articles

Synthetic Histopathological Images Generation with Artificial Intelligence to Accelerate Research and Improve Clinical Outcomes in Hematology

Blood (2023) 142 (Supplement 1): 902.

https://doi.org/10.1182/blood-2023-187521

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

Lymphopenia Confers Poorer Prognosis in Myelodysplastic Neoplasms (MDS) with Very Low and Low IPSS-M

David Fandrei, Tony Huynh, Marie Sebert, Lorea Aguinaga, Valeria Bisio, Marion Espéli, Karl Balabanian, Hélène Moins-Teisserenc, Antoine Toubert, Nicolas Dulphy, Pierre Fenaux, Lionel Ades, Lin-Pierre Zhao

Blood (2023) 142 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2023-187707

Published: 2023

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9828–9830.

https://doi.org/10.1182/blood-2022-166802

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome

Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Lupus-like manifestations in MDS/CMML: Evidence for clonal origin and therapeutic implications

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Synthetic Histopathological Images Generation with Artificial Intelligence to Accelerate Research and Improve Clinical Outcomes in Hematology

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Lymphopenia Confers Poorer Prognosis in Myelodysplastic Neoplasms (MDS) with Very Low and Low IPSS-M

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only